Loading...
•
Sep 30, 2024
Amphastar Q3 2024 Earnings Report
Reported net revenues of $191.2 million, GAAP net income of $40.4 million, and adjusted non-GAAP net income of $49.6 million.
Key Takeaways
Amphastar Pharmaceuticals reported a net revenue increase of 6% to $191.2 million for the third quarter of 2024. GAAP net income was $40.4 million, and adjusted non-GAAP net income reached $49.6 million. The company's growth was driven by sales, particularly from BAQSIMI® and Primatene MIST®.
Net revenues for Q3 2024 reached $191.2 million.
GAAP net income for Q3 2024 was $40.4 million, or $0.78 per share.
Adjusted non-GAAP net income for Q3 2024 was $49.6 million, or $0.96 per share.
BAQSIMI® and Primatene MIST® were key drivers of growth during the quarter.
Revenue by Segment
Forward Guidance
Management focuses on positioning the Company towards sustainable, long-term growth by pivoting to high-value and high-growth areas, particularly centered on developing proprietary products and biosimilars.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...